Related Experiment Video
Updated: May 12, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study
M E Peters1, P B Rosenberg, M Steinberg
1The Johns Hopkins University, Baltimore, MD.
Objectives:
To examine the association of neuropsychiatric symptom (NPS) severity with risk of transition to all-cause dementia, Alzheimer disease (AD), and vascular dementia (VaD).
Design:
Survival analysis of time to dementia, AD, or VaD onset.
Setting:
Population-based study.
Participants:
230 participants diagnosed with cognitive impairment, no dementia (CIND) from the Cache County Study of Memory Health and Aging were followed for a mean of 3.3 years.
Measurements:
The Neuropsychiatric Inventory (NPI) was used to quantify the presence, frequency, and severity of NPS. Chi-squared statistics, t-tests, and Cox proportional hazard ratios were used to assess associations.
Results:
The conversion rate from CIND to all-cause dementia was 12% per year, with risk factors including an APOE ε4 allele, lower Mini-Mental State Examination, lower 3MS, and higher CDR sum-of-boxes. The presence of at least one NPS was a risk factor for all-cause dementia, as was the presence of NPS with mild severity. Nighttime behaviors were a risk factor for all-cause dementia and of AD, whereas hallucinations were a risk factor for VaD.
Conclusions:
These data confirm that NPS are risk factors for conversion from CIND to dementia. Of special interest is that even NPS of mild severity are a risk for all-cause dementia or AD.
Related Concept Videos
Alzheimer Disease l: Introduction
Dementia l: Introduction
Dementia
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

